DANIEL RABINOWITZ, the SEC. AND CHIEF LEGAL OFFICER of $NTRA, sold 10,000 shares of the company on 06-18-2025 for an estimated $1,701,795. We received data on the trade from a recent SEC filing. This was a sale of approximately 4.5% of their shares of this class of stock. Following this trade, they now own 213,674 shares of this class of $NTRA stock.
$NTRA Insider Trading Activity
$NTRA insiders have traded $NTRA stock on the open market 237 times in the past 6 months. Of those trades, 0 have been purchases and 237 have been sales.
Here’s a breakdown of recent trading of $NTRA stock by insiders over the last 6 months:
- STEVEN LEONARD CHAPMAN (CEO AND PRESIDENT) has made 0 purchases and 32 sales selling 237,974 shares for an estimated $36,362,864.
- MATTHEW RABINOWITZ (EXECUTIVE CHAIRMAN) has made 0 purchases and 16 sales selling 112,848 shares for an estimated $17,191,147.
- MICHAEL BURKES BROPHY (CHIEF FINANCIAL OFFICER) has made 0 purchases and 32 sales selling 90,125 shares for an estimated $15,231,949.
- SOLOMON MOSHKEVICH (PRESIDENT, CLINICALDIAGNOSTICS) has made 0 purchases and 32 sales selling 55,162 shares for an estimated $8,784,881.
- DANIEL RABINOWITZ (SEC. AND CHIEF LEGAL OFFICER) has made 0 purchases and 16 sales selling 51,979 shares for an estimated $8,587,940.
- JONATHAN SHEENA has made 0 purchases and 76 sales selling 38,667 shares for an estimated $5,968,266.
- JOHN FESKO (PRESIDENT, CHIEF BUS. OFFICER) has made 0 purchases and 13 sales selling 30,545 shares for an estimated $4,987,091.
- GAIL BOXER MARCUS has made 0 purchases and 20 sales selling 20,299 shares for an estimated $3,137,557.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$NTRA Hedge Fund Activity
We have seen 325 institutional investors add shares of $NTRA stock to their portfolio, and 303 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- PRICE T ROWE ASSOCIATES INC /MD/ added 3,795,315 shares (+56.3%) to their portfolio in Q1 2025, for an estimated $536,695,494
- BLACKROCK, INC. added 1,260,125 shares (+13.7%) to their portfolio in Q1 2025, for an estimated $178,194,276
- KYNAM CAPITAL MANAGEMENT, LP removed 854,528 shares (-42.3%) from their portfolio in Q1 2025, for an estimated $120,838,804
- GOLDMAN SACHS GROUP INC removed 734,551 shares (-43.3%) from their portfolio in Q1 2025, for an estimated $103,872,856
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC added 732,156 shares (+140.4%) to their portfolio in Q1 2025, for an estimated $103,534,179
- CITADEL ADVISORS LLC added 691,990 shares (+48.4%) to their portfolio in Q1 2025, for an estimated $97,854,305
- JPMORGAN CHASE & CO added 660,538 shares (+9.9%) to their portfolio in Q1 2025, for an estimated $93,406,678
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$NTRA Analyst Ratings
Wall Street analysts have issued reports on $NTRA in the last several months. We have seen 8 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Piper Sandler issued a "Overweight" rating on 05/15/2025
- UBS issued a "Buy" rating on 05/09/2025
- Barclays issued a "Overweight" rating on 05/09/2025
- RBC Capital issued a "Outperform" rating on 03/13/2025
- Morgan Stanley issued a "Overweight" rating on 03/05/2025
- Canaccord Genuity issued a "Buy" rating on 02/28/2025
- Baird issued a "Outperform" rating on 02/28/2025
To track analyst ratings and price targets for $NTRA, check out Quiver Quantitative's $NTRA forecast page.
$NTRA Price Targets
Multiple analysts have issued price targets for $NTRA recently. We have seen 8 analysts offer price targets for $NTRA in the last 6 months, with a median target of $192.5.
Here are some recent targets:
- David Westenberg from Piper Sandler set a target price of $210.0 on 05/15/2025
- Elizabeth Garcia from UBS set a target price of $218.0 on 05/09/2025
- Luke Sergott from Barclays set a target price of $190.0 on 05/09/2025
- Conor McNamara from RBC Capital set a target price of $251.0 on 03/13/2025
- Tejas Savant from Morgan Stanley set a target price of $185.0 on 03/05/2025
- Kyle Mikson from Canaccord Genuity set a target price of $195.0 on 02/28/2025
- Catherine Ramsey from Baird set a target price of $188.0 on 02/28/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
